Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Sun Dec 18 08:30:44 UTC 2022
by
admin
on
Sun Dec 18 08:30:44 UTC 2022
|
Protein Sub Type | |
Sequence Origin | HUMAN |
Sequence Type | COMPLETE |
Record UNII |
19GBD6T9L7
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
P14416
Created by
admin on Sun Dec 18 08:30:50 UTC 2022 , Edited by admin on Sun Dec 18 08:30:50 UTC 2022
|
PRIMARY | |||
|
P14416
Created by
admin on Sun Dec 18 08:30:50 UTC 2022 , Edited by admin on Sun Dec 18 08:30:50 UTC 2022
|
PRIMARY | |||
|
19GBD6T9L7
Created by
admin on Sun Dec 18 08:30:50 UTC 2022 , Edited by admin on Sun Dec 18 08:30:50 UTC 2022
|
PRIMARY |
From | To |
---|---|
1_107 | 1_182 |
1_399 | 1_401 |
Glycosylation Type | HUMAN |
Glycosylation Link Type | Site |
---|---|
N | 1_5 |
N | 1_17 |
N | 1_23 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
RADIOLIGAND->TARGET |
|
||
|
AGONIST -> TARGET | |||
|
ANTAGONIST->TARGET |
BINDING
Ki
|
||
|
PARTIAL AGONIST->TARGET | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
ANTAGONIST
|
||
|
PARTIAL AGONIST->TARGET | |||
|
INHIBITOR -> TARGET |
INHIBITOR
Ki
|
||
|
RADIOLIGAND->TARGET |
Ki
|
||
|
INHIBITOR -> TARGET |
ANTAGONIST
|
||
|
AGONIST -> TARGET |
|
||
|
LIGAND->TARGET | |||
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET |
Ki
|
||
|
INHIBITOR -> TARGET |
INHIBITOR
Ki
|
||
|
INHIBITOR -> TARGET |
cell:CHO K1; ligand:3H-spiperone
Ki
|
||
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET |
Ki
|
||
|
PARTIAL AGONIST->TARGET | |||
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
PARTIAL AGONIST->TARGET | |||
|
AGONIST -> TARGET | |||
|
PARTIAL AGONIST->TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
LIGAND->TARGET |
|
||
|
AGONIST -> TARGET |
D2R concentration levels were significantly lower in AD patients than in healthy controls (SMD = ?1.13, 95%CI: ?1.52 to ?0.74), with low heterogeneity (I2 = 7.80%), when USA studies were considered.
|
||
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET |
MAJOR
Ki
|
||
|
AGONIST -> TARGET |
D2S Primary receptor interaction.. Emax 79%
EC50
|
||
|
PARTIAL AGONIST->TARGET |
|
||
|
INHIBITOR -> TARGET |
Ki
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
PARTIAL AGONIST
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
PARTIAL AGONIST->TARGET | |||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET |
Ki
|
||
|
AGONIST -> TARGET | |||
|
ANTAGONIST->TARGET |
SELECTIVE
|
||
|
INHIBITOR -> TARGET | |||
|
INVERSE AGONIST->TARGET |
Ki
|
||
|
INHIBITOR -> TARGET |
|
||
|
RADIOLIGAND->TARGET | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
LIGAND->TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Molecular Formula | CHEMICAL |
|
||||
MOL_WEIGHT | CHEMICAL |
|